Amerikanische Gesellschaft für Hirudotherapie

The Use of Bivalirudin in Pediatric Cardiac Surgery and in the Interventional Cardiology Suite

Review published in J Cardiothorac Vasc Anesth (2020)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewArzneimittelentwicklungKlinische StudienGoswami D et al. · Journal of cardiothoracic and vascular anesthesia, 2020

Abstract

Anticoagulation is an essential component for patients undergoing cardiopulmonary bypass or extracorporeal membrane oxygenation and for those with ventricular assist devices. However, thrombosis and bleeding are common complications. Heparin continues to be the agent of choice for most patients, likely owing to practitioners' comfort and experience and the ease with which the drug's effects can be reversed. However, especially in pediatric cardiac surgery, there is increasing interest in using bivalirudin as the primary anticoagulant. This drug circumvents certain problems with heparin administration, such as heparin resistance and heparin-induced thrombocytopenia, but it comes with additional challenges. In this manuscript, the authors review the literature on the emerging role of bivalirudin in pediatric cardiac surgery, including its use with cardiopulmonary bypass surgery, extracorporeal membrane oxygenation, ventricular assist devices, and interventional cardiology. Moreover, they provide an overview of bivalirudin's pharmacodynamics and monitoring methods.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnticoagulantsCardiac Surgical ProceduresCardiologyCardiopulmonary BypassChildHeparinHirudinsHumansPeptide FragmentsRecombinant Proteins

Zusammenfassung

Review of bivalirudin pharmacodynamics and use in pediatric cardiac surgery including CPB, ECMO, VAD and interventional cardiology, particularly for heparin resistance and HIT.

Warum dies für die Hirudotherapie relevant ist

This review examines the emerging role of bivalirudin as an alternative anticoagulant in pediatric cardiac surgery, including its use with cardiopulmonary bypass, extracorporeal membrane oxygenation, ventricular assist devices, and interventional cardiology. The authors survey the literature on bivalirudin's pharmacodynamics, monitoring methods, and its ability to circumvent heparin-associated problems such as heparin resistance and heparin-induced thrombocytopenia. The abstract does not mention hirudin, leeches, or any connection to the leech secretome, so no defensible hirudotherapy link can be drawn from this article. This is a review article without original clinical data, and it does not involve leeches or hirudotherapy.

Zitation

The Use of Bivalirudin in Pediatric Cardiac Surgery and in the Interventional Cardiology Suite.

Goswami D et al. · Journal of cardiothoracic and vascular anesthesia, 2020

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.